Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nauheim – page 51

1 333 clinical trials in Bad Nauheim, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nauheim at a glance
1 333
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 333 trials in Bad Nauheim

Open in trial search

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Gastrooesophageal cancer+1

Not yet recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Cholangitis sclerosing

Not yet recruiting

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Heart disease congenital

Not yet recruiting

Study Comparing Custodiol-N and Custodiol for Heart Surgery in Children with Congenital Heart Defects

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Alanine
  • Sponsor:Dr. Franz Koehler Chemie GmbH

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Cardiac failure chronic

Not yet recruiting

Study on the Effects of Colchicine on Blood Vessel Function in Patients with Chronic Heart Failure and CHIP Mutations

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Goethe University Frankfurt

Hypertrophic cardiomyopathy

Not yet recruiting

Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nauheim

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on hypertrophic cardiomyopathy treatments, including trials of mavacamten and aficamten. Research also covers advanced therapies for heart failure and pulmonary hypertension management.

  • Cardiac Structure Improvement
  • Heart Function Enhancement
  • Pulmonary Hypertension Treatment

Long-term safety and efficacy evaluations of novel cardiovascular medications are prioritized.

02 Oncology Studies

Advanced research in breast cancer treatment, particularly focusing on HER2-negative and triple-negative variants. Studies evaluate innovative combination therapies including atezolizumab and targeted treatments.

  • Neoadjuvant Therapies
  • Immunotherapy Applications
  • Treatment Resistance

Emphasis on improving survival rates and reducing recurrence in early-stage breast cancer.

03 Inflammatory Conditions

Clinical investigations of inflammatory diseases including myositis and arteritis. Studies evaluate new biological treatments and their long-term effectiveness in managing chronic inflammatory conditions.

  • Autoimmune Disorders
  • Novel Biologics
  • Disease Modification

Focus on developing targeted therapies for better disease control and improved patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.